WORLD_M_Global_2009

First Page		Document Content
Date: 2013-02-25 04:20:13 Pharmacology Crucell Influenza vaccine Malaria vaccine International Financial Reporting Standards Hepatitis A vaccine Influenza FluMist Financial statement Vaccines Medicine Health		WORLD_M_Global_2009 Add to Reading List Source URL: crucell.com Download Document from Source Website File Size: 5,13 MB Share Document on Facebook

	Frequently asked questions (FAQs) RIA2018SV- Strategic action for the comparison, selection and development of malaria vaccine candidates Document history Version DocID: 1v2j2 - View Document
	1 1 RTS,S/AS01 MALARIA VACCINE CANDIDATE PHASE III SAFETY EVALUATION IN AFRICAN INFANTS 6-12 WEEKS OF AGE AT FIRST VACCINATION OVER FOURTEEN MONTHS OF DocID: 1uoQf - View Document
	ENHANCED PROTECTIVE EFFICACY OF A PLASMODIUM FALCIPARUM MALARIA VACCINE USING A HETEROLOGOUS PRIME-BOOST IMMUNIZATION WITH A BACULOVIRAL DocID: 1tPZr - View Document
	Science article: “Protection Against Malaria by Intravenous Immunization with a Non-Replicating Sporozoite Vaccine” What: A phase 1 clinical trial of Sanaria’s malaria vaccine, the Sanaria PfSPZ Vaccine, demonstrat DocID: 1suvJ - View Document
	Sanaria Inc. to launch crowdfunding campaign for SporoBotTM, a mosquito-dissecting robot for accelerating manufacture of Sanaria’s malaria vaccine. ROCKVILLE, MD – April 30, 2014 – For immediate release - Biotechno DocID: 1sjTZ - View Document